Abnormalities of apolipoprotein E in the acquired immunodeficiency syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 11, 1997, Pages 3734-3740

  Grunfeld, Carl ^a   Doerrler, William ^b   Pang, Miyin ^b   Jensen, Peter ^b   Weisgraber, Karl H ^b   Feingold, Kenneth R ^b  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; CHOLESTEROL; TRIACYLGLYCEROL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HYPERTRIGLYCERIDEMIA; PHENOTYPE; PRIORITY JOURNAL; SIALYLATION;

EID: 0030684074     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.82.11.3734     Document Type: Article

References (73)

1. Rall Jr SC, Weisgraber KH, Mahley RW. 1982 Human apolipoprotein E: the complete amino acid sequence. J Biol Chem. 257:4171-4178.
2. Zannis VI, Breslow JL. 1981 Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and post-translational modification. Biochemistry. 20:1033-1041.
3. Weisgraber KH. 1994 Apolipoprotein E: structure-function relationships. Adv Protein Chem. 45:249-302.
4. Rall Jr SC, Mahley RW. 1989 Type III Hyperlipoproteinemia (Dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Vale D, eds. Metabolic basis of inherited disease. 6th ed. New York: McGraw Hill; 1195-1213.
5. Herz J, Hamann U, Rogne S, Myklebost O, Gausepohl H, Stanley KK. 1988 Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor. EMBO J. 7:4119-4127.
6. Kowal RC, Herz J, Goldstein JL, Esser V, Brown M. 1989 Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins. Proc Natl Acad Sci USA. 86:5810-5814.
7. Lund H, Takahashi K, Hamilton RL, Havel RJ. 1989 Lipoprotein binding and endosomal itinerary of the low density lipoprotein receptor-related protein in rat liver. Proc Natl Acad Sci USA. 86:9318-9322.
8. Weisgraber KH, Innerarity TL, Mahley RW. 1982 Abnormal lipoprotein receptor-binding activity of human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem. 257:2518-2521.
9. 2-macroglobulin receptor. J Biol Chem. 266:13936-13940.
10. Strickland DK, Ashcom JD, Williams S, Burgess WH, Migliorini M, Argraves WS. 1990 Sequence identity between the alpha 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor. J Biol Chem. 265:17401-17404.
11. Evans AJ, Huff MW, Wolfe BM. 1989 Accumulation of an apoE-poor subfraction of very low density lipoprotein in hypertriglyceridemic men. J Lipid Res. 30:1691-1701.
12. Phillips NR, Havel RJ, Kane JP. 1983 Sex-related differences in the concentrations of apolipoprotein E in human blood plasma and plasma lipoproteins. J Lipid Res. 24:1525-1531.
13. Weisweiler P, Drosner M, Schwandt P. 1982 Dietary effects on very low-density lipoproteins in Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 23:101-103.
14. Eto M, Watanabe K, Sata T, Makino I. 1989 Apolipoprotein-E2 and hyperlipoproteinemia in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 69:1207-1212.
15. Black SC, Hewett S, Kotubi Y, Brunt RV, Reckless JPD. 1990 Isoform patterns of apolipoprotein E in diabetes mellitus. Diabet Med. 7:532-539.
16. Weisweiler P, Jungst D, Schwandt P. 1983 Quantitation of apolipoprotein E-isoforms in diabetes mellitus. Horm Metabol Res. 15:201-201.
17. Sano R, Abe R, Oikawa S-I, Fujii Y, Toyota T. 1985 apoE-2 / E-3 ratio of very low density lipoprotein in diabetes mellitus. Tohoku J Exp Med. 146:131-136.
18. Eto M, Watanabe K, Iwashima Y, et al. 1986 Apolipoprotein E polymorphism and hyperlipemia in Type II diabetics. Diabetes. 35:1374-1382.
19. Winocour PH, Tetlow L, Durrington PN, Ishola M, Hillier V, Anderson DC. 1989 Apolipoprotein E polymorphism and lipoproteins in insulin-treated diabetes mellitus. Atherosclerosis. 75:167-173.
20. Eto M, Watanabe K, Makino I. 1991 Relationship of metabolic control and body weight to hypercholesterolemia in NIDDM patients with apolipoprotein E4. Diabetes Care. 14:127-129.
21. Shriver MD, Boerwinkle E, Hewett-Emmett D, Hanis CL. 1991 Frequency and effects of apolipoprotein E polymorphism in Mexican-American NIDDM subjects. Diabetes. 40:334-337.
22. Cortner JA, Coates PM, Ngoc-Anh L, et al. 1987 Kinetics of chylomicron remnant clearance in normal and in hyperlipoproteinemic subjects. J Lipid Res. 28:195-206.
23. Renninkmeijer BJ, Stuyt PMJ, Demacker PNM, Stalenhoef AFH, van't Laar A. 1987 Catabolism of chylomicron remnants in normolipidemic subjects in relation to the apoprotein E phenotype. J Lipid Res. 28:361-370.
24. Weintraub MS, Eisenberg S, Breslow JL. 1987 Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein E. J Clin Invest. 80:1571-1577.
25. Cassader M, Ruiu G, Gambino R, Alemanno N, Triolo G, Pagano G. 1989 Apolipoprotein C and E isoforms in diabetic uraemic patients. Diabetes Nutr Metab. 2:33-37.
26. Hussein MJ, Peakman M, Leslie RDG, Viberti GC, Watkins PJ, Vergani D. 1991 Circulating levels of interleukin-1 alpha, tumor necrosis factor alpha and interferon gamma are high in newly diagnosed Type I diabetes. Diabetes. [Suppl 1]40:147A.
27. Dasgupta B, Messent J, Corrigall V, Panaji G, Keen H. 1991 Interleukin-6 in insulin dependent diabetes mellitus. Diabetes. [Suppl 1]40:264A.
28. Ganrot PO, Gydelli K, Ekelund H. 1967 Serum concentration of alpha 2-macroglobulin, haptoglobulin and alpha-1 antitrypsin in diabetes mellitus. Acta Endocrinol. 55:537-544.
29. Johnsson A, Wales JK. 1976 Blood glycoprotein levels in diabetes mellitus. Diabetologia. 12:245-250.
30. McMillan DE. 1989 Increased levels of acute-phase serum proteins in diabetes. Metabolism. 38:1042-1046.
31. Ganda OM, Arkin CF. 1992 Hyperfibrinogenemia: an important risk factor for vascular complications in diabetes. Diabetes Care. 15:1245-1250.
32. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson Jr RN. 1989 Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med. 86:27-31.
33. Granfeld C, Kotler DP, Shigenaga JK, et al. 1991 Circulating interferon alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med. 90:154-162.
34. Granfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. 1992 Lipids, lipoproteins, triglyceride clearance and cytokines in human immuno-deficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endorinol Metab. 74:1045-1052.
35. Patton JS, Shepard HM, Wilking H, et al. 1986 Interferons and tumor necrosis factors have similar catabolic effect on 3T3-L1 cells. Proc Natl Acad Sci USA. 83:8313-8317.
36. Feingold KR, Soued M, Serio MK, Moser AH, Dinarello CA, Grunfeld C. 1989 Multiple cytokines stimulate hepatic lipid synthesis in vivo. Endocrinology. 125:267-274.
37. Centers for Disease Control. 1987 Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep. [Suppl 2S]36:3S-14S.
38. Innerarity TL, Bersot TP, Arnold KS, et al. 1984 Receptor binding activity of high-density lipoproteins containing apoprotein E from abetalipoproteinemic and normal neonate plasma. Metabolism. 33:186-195.
39. Wardell MR, Rall Jr SC, Brennan SO, et al. 1990 Apolipoprotein E2-Dunedin (228 Arg->Cys): an apolipoprotein E2 variant with normal receptor-binding activity. J Lipid Res. 31:535-543.
40. Towbin H, Staehelin T, Gordon J. 1979 Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA. 76:4350-4354.
41. Holdsworth G, Stocks J, Dodson P, Gallon DJ. 1982 An abnormal triglyceriderich lipoprotein containing excess sialylated apolipoprotein C-III. J Clin Invest. 69:932-939.
42. Nestruck AC, Rubinstein D. 1976 The synthesis of apoproteins of very low density lipoproteins isolated from the Golgi apparatus of rat liver. Can J Biochem. 54:617-628.
43. Guo LSS, Hamilton RL, Kane JP, Fielding CJ, Chen GC. 1982 Characterization and quantitation of apolipoproteins A-1 and E of normal and cholesterolfed guinea pigs. J Lipid Res. 23:531-542.
44. Kraft HG, Menzel HJ, Hoppichler F, Voge W, Utermann G. 1989 Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis. J Clin Invest. 83:137-142.
45. Linton MF, Gish R, Hubl ST, et al. 1991 Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J Clin Invest. 88:270-281.
46. Basu SK, Brown MS, Ho YK, Havel RJ, Goldstein JL. 1981 Mouse macrophages synthesize and secrete a protein resembling apolipoprotein E. Proc Natl Acad Sci USA. 78:7545-7549.
47. Wang-Ivenson P, Gibson JC, Brown WV. 1985 Plasma apolipoprotein secretion by human monocyte-derived macrophages. Biochem Biophys Acta. 834:256-262.
48. Bowen DL, Lane HC, Fauci AS. 1985 Immunopathogenesis of the acquired immunodeficiency syndrome. Ann Intern Med. 102:704-709.
49. Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A. 1988 Cachectin / TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science. 240:1546-1548.
50. Kushner I. 1982 The phenomenon of the acute phase response. Ann NY Acad Sci. 389:39-48.
51. Perlmutter DH, Dinarello CA, Punsal PI, Colten HR. 1986 Cachectin / tumor necrosis factor regulates hepatic acute-phase gene expression. J Clin Invest. 78:1349-1354.
52. Darlington GJ, Wilson DR, Lachman LB. 1987 Monocyte conditioned medium, interleukin-1 and tumor necrosis factor stimulate the acute phase response in human hepatoma cells in vitro. J Cell Biol. 103:787-793.
53. Castell JV, Gomez-Lechon MJ, David M, et al. 1989 Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett. 242:237-239.
54. Marinkovic S, Jahreis GP, Wong GG, Baumann H. 1989 IL-6 modulates the synthesis of a specific set of acute phase plasma proteins in vivo. J Immunol. 142:808-812.
55. Mackiewicz A, Ganapathi MK, Schultz D, Kushner I. 1987 Monokines regulate glycosylation of acute phase proteins. J Exp Med. 166:253-258.
56. Mackiewicz A, Schultz D, Mathison J, Ganapathi MK, Kushner I. 1989 Effect of cytokines on glycosylation of acute phase proteins in human hepatoma cell lines. Clin Exp Immunol. 75:70-75.
57. 2 / BSF-2 / IL-6 affects glycosylation of acute phase proteins in human hepatoma cell lines. Scand J Immunol. 29:265-271.
58. Zannis VI, Kurnit DM, Breslow JL. 1982 Hepatic apo-A-I and apo-E and intestinal apo-A-I are synthesized in precursor isoprotein forms by organ cultures of human fetal tissues. J Biol Chem. 257:536-544.
59. Zannis VI, McPherson J, Goldberg G, Karathanasis SK, Breslow JL. 1984 Synthesis, intracellular processing, and signal peptide of human apolipoprotein E. J Biol Chem. 259:5495-5499.
60. Ghiselli G, Beigel Y, Soma M, Gotto Jr AM. 1986 Plasma catabolism of human apolipoprotein E isoproteins: lack of conversion of the doubly sialylated form to the asialo form in plasma. Metabolism. 35:399-403.
61. Ain KB, Mori Y, Refetoff S. 1987 Reduced clearance rate of thyroxine-binding globulin (TBG) with increased sialylation: a mechanism for estrogen-induced elevation of serum TBG concentration. J Clin Endocrinol Metab. 65:689-696.
62. Refetoff S, Fang VS, Marshall JS. 1975 Studies on human thyroxine-binding globulin (TBG). J Clin Invest. 56:177-187.
63. Martinez J, Palascak JE, Kwasmak D. 1978 Abnormal sialic content of the dysfibrinogenemia associated with liver disease. J Clin Invest. 61:535-538.
64. Pang X-P, Hershman JM, Mirell CJ, Pekary AE. 1989 Impairment of hypothalamic-pituitary-thyroid function in rats treated with human recombinant tumor necrosis factor-alpha (cachectin). Endocrinology. 125:76-84.
65. Havel RJ, Chao Y-S, Windier EE, Kotite L, Guo LSS. 1980 Isoprotein specificity in the hepatic uptake of apolipoprotein E and the pathogenesis of familial dysbetalipoproteinemia. Proc Natl Acad Sci USA. 66:4349-4353.
66. Rall SC, Weisgraber KH, Innerarity TL, Mahley RW. 1985 The carbohydrate moiety of human plasma apolipoprotein E. Circulation. 72:111-143 (Abstract).
67. Ulevitch RJ, Johnston AR, Weinstein DB. 1979 New function for high density lipoproteins. Their participation in intravascular reactions of bacterial lipopolysaccharides. J Clin Invest. 64:1516-1524.
68. Harris HW, Grunfeld C, Feingold KR, Rapp JH. 1990 Human VLDL and chylomicrons can protect against endotoxin-induced death in mice. J Clin Invest. 86:696-792.
69. Harris HW, Grunfeld C, Feingold KR, et al. 1993 Chylomicrons alter the fate of endotoxin, decreasing tumo rnecrosis factor release and preventing death. J Clin Invest. 91:1028-1034.
70. Sernatinger J, Hoffman A, Harman D, Kane JP, Levy JA. 1988 Neutralization of mouse xenotropic virus by lipoproteins involves binding to the virions. J Gen Virol. 69:2651-2661.
71. Chisari FV, Curtiss LK, Jensen FC. 1981 Physiologic concentrations of normal human plasma lipoproteins inhibit the immortalization of peripheral B lymphocytes by the Epstein-Barr virus. J Clin Invest. 68:329-336.
72. Shortridge KF, Ho WK, Oya A, Kobayashi M. 1975 Studies on the inhibitory activities of human serum lipoproteins for Japanese encephalitis virus. Southeast Asian J Trop Med Pub Health. 6:461-466.
73. Seganti L, Grass M, Mastromarino P, Pan'a A, Superti F, Orsi N. 1983 Activity of human serum lipoproteins on the infectivity of rhabdoviruses. Microbiology. 6:91-99.